复方替加氟奥替拉西胶囊治疗晚期胃癌的临床观察

被引：3

作者：

刘安文

王顺金

艾春红

机构：

[1] 南昌大学第二附属医院肿瘤科

来源：

实用癌症杂志 | 2008年 / 01期

关键词：

复方替加氟奥替拉西胶囊(S-1); 替加氟; 草酸铂; 晚期胃癌;

D O I：

暂无

中图分类号：

R735.2 [胃肿瘤];

学科分类号：

100112 [医学生物化学与分子生物学];

摘要：

目的观察复方替加氟奥替拉西胶囊治疗晚期胃癌的疗效和毒副反应。方法55例晚期胃癌患者随机入组,分为复方替加氟奥替拉西胶囊联合草酸铂组(研究组,29例),替加氟片联合草酸铂组(对照组,26例),另有12例既往用过草酸铂或口服氟脲嘧啶类药物的患者进入单药复方替加氟奥替拉西胶囊组,治疗2个周期后评定疗效及毒副反应。结果67例中63例可评价疗效和毒副反应,对照组和试验组的近期有效率分别为42.8%和12.5%(P<0.05),两组比较有统计学差异。试验组和对照组的血液学及非血液学毒性两组比较无统计学差异。单药组的病情稳定率为81.8%。结论复方替加氟胶囊联合草酸铂治疗晚期胃癌疗效确切,且不良反应轻,对于既往用过草酸铂和氟脲嘧啶类药物而复发的患者,复方替加氟单药也有一定的疗效,值得临床进一步推广应用。

引用

页码：56 / 58+68 +68

页数：4

共 5 条

[1]

Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1<ce:hsp sp="0.25"/>M tegafur–0.4<ce:hsp sp="0.25"/>M gimestat–1<ce:hsp sp="0.25"/>M otastat potassium) in advanced gastric cancer patients[J] Y Sakata;A Ohtsu;N Horikoshi;K Sugimachi;Y Mitachi;T Taguchi European Journal of Cancer 1998,

[2]

Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracilon human tumor xenografts.[J] M Fukushima;H Satake;J Uchida;Y Shimamoto;T Kato;T Takechi;H Okabe;A Fujioka;K Nakano;H Ohshimo;S Takeda;T Shirasaka International Journal of Oncology 1998,

[3]

Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer[J] B. Glimelius;K. Ekstr?m;K. Hoffman;W. Graf;P.-O. Sj?dén;U. Haglund;C. Svensson;L.-K. Enander;T. Linné;H. Sellstr?m;R. Heuman Annals of Oncology 1997,

[4]

Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators[J] Tetsuhiko Shirasaka;Yuji Shimamato;Hideyuki Ohshimo;Masahiro Yamaguchi;Toshiyuki Kato;Kazuhiko Yonekura;Masakazu Fukushima Anti-Cancer Drugs 1996,

[5]

Chemotherapy of gastric cancer[J] D L Schipper;D J T Wagener Anti-Cancer Drugs 1996,

← 1 →